BioNano Genomics Inc vs JPMorgan Equity Premium Income ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while JPMorgan Equity Premium Income ETF trades at $56.6. The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | JEPI | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.92 | $59.88 |
52-Week Low | $1.09 | $55.29 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
JEPI trades at $56.76 with no price change, showing stability amid mixed technical signals. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators suggest neutral momentum. Recent dividend payments of $0.39 and $0.45 demonstrate its income-focused strategy, while financial media highlights its 8%+ yield and covered call approach as key attractions for income investors.
JEPI's covered call strategy provides consistent income but limits upside potential during bull markets. The ETF faces competition from alternatives like SPYI and tax efficiency concerns, though its active management offers drawdown protection. Current technical strength supports near-term stability, but investors should weigh income benefits against capped returns in rising markets.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →